Hyperaldosteronism

DOID EFO MESH SNOMED PheWeb

E4_HYPERALDO

hyperaldosteronism: Overproduction of aldosterone by the adrenal glands, which may lead to hypokalemia and/or hypernatremia. [ NCIT:P378 ]

Endpoint definition

↥

FinnGen phenotype data

392423 individuals

diagram downward connector

Apply sex-specific rule None

392423

diagram downward connector

Check conditions None

392423

diagram downward connector

Check pre-conditions, main-only, mode, registry filters

Hospital Discharge: ICD-10 E26

Hospital discharge: ICD-9 2551

Hospital discharge: ICD-8 25500

Cause of death: ICD-10 E26

Cause of death: ICD-9 2551

Cause of death: ICD-8 25500

2 out of 7 registries used, show all original rules.

717

diagram downward connector

Check minimum number of events None

717

diagram downward connector

Include endpoints None

717

diagram downward connector

diagram downward connector

Remove individuals based on genotype QC

690

diagram downward connector

E4_HYPERALDO

Control definitions

Control exclude E4_ENDOGLAND

Extra metadata

Level in the ICD hierarchy 4

First used in FinnGen datafreeze DF2

Parent code in ICD-10 E20-E35

Name in latin Hyperaldosteronismus

NAME	E4_HYPERALDO
CONTROL_EXCLUDE	E4_ENDOGLAND
CONTROL_PRECONDITIONS
CONTROL_CONDITIONS
SEX
INCLUDE
PRE_CONDITIONS
CONDITIONS
OUTPAT_ICD
OUTPAT_OPER
HD_MAINONLY
HD_ICD_10_ATC
HD_ICD_10	E26
HD_ICD_9	2551
HD_ICD_8	25500
HD_ICD_10_EXCL
HD_ICD_9_EXCL
HD_ICD_8_EXCL
COD_MAINONLY
COD_ICD_10	E26
COD_ICD_9	2551
COD_ICD_8	25500
COD_ICD_10_EXCL
COD_ICD_9_EXCL
COD_ICD_8_EXCL
OPER_NOM
OPER_HL
OPER_HP1
OPER_HP2
KELA_REIMB
KELA_REIMB_ICD
KELA_ATC_NEEDOTHER
KELA_ATC
KELA_VNRO_NEEDOTHER
KELA_VNRO
CANC_TOPO
CANC_TOPO_EXCL
CANC_MORPH
CANC_MORPH_EXCL
CANC_BEHAV

Show upset plot detailing case counts by codes

Or the full data table

Similar endpoints

↥

List of similar endpoints to Hyperaldosteronism based on the number of shared cases.

Broader endpoints:

Narrower endpoints:

None

Show all endpoint correlations

Summary Statistics

↥

Key figures

	All	Female	Male
Number of individuals	690	383	307
Unadjusted prevalence (%)	0.18	0.18	0.18
Mean age at first event (years)	56.36	54.06	59.23

Mortality

Follow-up	Absolute risk	HR [95% CI]	p	N
1998–2019	0.04	2.50 [1.25, 4.99]	9.6e-3	51
15 years	0.01	1.62 [0.80, 3.31]	1.8e-1	26
5 years	-	-	-	-
1 year	-	-	-	-

Age distribution of first events

Year distribution of first events

Cumulative Incidence

Correlations

↥

Index endpoint: E4_HYPERALDO – Hyperaldosteronism
GWS hits: 2

Survival analyses between endpoints

↥

Plot

before Hyperaldosteronism
after Hyperaldosteronism

Loading survival analyses plot

Table

Loading survival analyses table

Drugs most likely to be purchased after Hyperaldosteronism

↥

Endpoint not on priority list, no data to show.